創傷護理生技藥品市場規模、佔有率和成長分析（按產品、傷口類型、最終用戶和地區）- 產業預測 2025-2032

預計 2023 年全球創傷護理生技藥品市場規模將達到 17.9 億美元，並從 2024 年的 18.8 億美元成長到 2032 年的 28.2 億美元，預測期內（2025-2032 年）的複合年成長率為 5.2%。

受醫療技術進步和創新治療方案需求不斷成長的推動，全球創傷護理生技藥品市場呈現強勁成長勢頭。這些產品含有生長因子和幹細胞等生物材料，在醫療保健領域越來越受歡迎，可有效治療慢性傷口、糖尿病足潰瘍和燒傷。造成這種情況的原因包括慢性病發病率上升、老齡人口增加以及傷口癒合時間變慢。個人化醫療和先進醫療保健的趨勢以及盡量減少住院時間和醫療費用的努力進一步推動了這一趨勢。然而，高成本、嚴格的法規以及醫療專業人員的認知有限等挑戰可能會阻礙市場擴張，並對生技藥品在創傷護理中的廣泛應用造成障礙。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究

創傷護理生技藥品市場規模（按產品和複合年成長率） (2025-2032)

• 市場概況
• 生物皮膚替代品
  • 人類供體組織衍生產品
  • 無細胞動物產品
  • 生物合成產品
• 外用藥物

創傷護理生技藥品市場規模（按傷口類型和複合年成長率） (2025-2032)

• 市場概況
• 潰瘍
  • 糖尿病足潰瘍
  • 靜脈潰瘍
  • 壓瘡
  • 其他潰瘍
• 外科性創傷與創傷傷口
• 燒傷

創傷護理生技藥品市場規模（依最終用戶和複合年成長率） (2025-2032)

• 市場概況
• 醫院
• 門診手術中心
• 燒燙傷中心和傷口護理診所

創傷護理生技藥品市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Smith & Nephew（United Kingdom）
• Integra LifeSciences（United States）
• Organogenesis Holdings Inc.（United States）
• MiMedx Group, Inc.（United States）
• Osiris Therapeutics, Inc.（United States）
• Aroa Biosurgery（New Zealand）
• Avita Medical（Australia）
• Derma Sciences, Inc.（United States）
• Alliqua BioMedical, Inc.（United States）
• Amnio Technology, LLC（United States）
• Tissue Regenix Group plc（United Kingdom）
• CollPlant Biotechnologies Ltd.（Israel）
• RenovaCare, Inc.（United States）
• PolarityTE, Inc.（United States）
• Cytori Therapeutics, Inc.（United States）
• Histogenics Corporation（United States）
• Vericel Corporation（United States）
• RepliCel Life Sciences Inc.（Canada）

結論和建議

Global Wound Care Biologics Market size was valued at USD 1.79 billion in 2023 and is poised to grow from USD 1.88 billion in 2024 to USD 2.82 billion by 2032, growing at a CAGR of 5.2% during the forecast period (2025-2032).

The global wound care biologics market is on a robust growth trajectory, fueled by advancements in healthcare technology and increasing demand for innovative healing solutions. Comprising biological substances like growth factors and stem cells, these products effectively address chronic wounds, diabetic foot ulcers, and burns, thereby gaining traction in healthcare settings. Contributing factors include the rising incidence of chronic ailments and a growing elderly demographic vulnerable to slow-healing wounds. The movement towards personalized medicine and advanced therapies, as well as efforts to minimize hospital stays and healthcare costs, further support this trend. However, challenges such as high costs, stringent regulations, and limited awareness among healthcare professionals may inhibit market expansion, creating hurdles for widespread adoption of wound care biologics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Wound Care Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Wound Care Biologics Market Segments Analysis

Global Wound Care Biologics Market is segmented by Product, Wound Type, End User and region. Based on Product, the market is segmented into Biological Skin Substitutes and Topical Agents. Based on Wound Type, the market is segmented into Ulcers, Surgical & Traumatic Wounds and Burns. Based on End User, the market is segmented into Hospitals, Ambulatory Surgery Centers and Burn Care Centers & Wound Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Wound Care Biologics Market

The global wound care biologics market is significantly propelled by the rising prevalence of chronic wounds, particularly diabetic foot ulcers and pressure ulcers. These conditions create a growing demand for innovative treatment solutions. Biologic wound care products provide exceptional therapeutic alternatives that enhance the healing process for difficult cases, making them increasingly vital in modern wound management. As healthcare professionals seek effective ways to address these complex ailments, the need for advanced biologics becomes more pronounced, driving the market's expansion. This trend underscores the critical role of biologics in improving patient outcomes in wound care settings.

Restraints in the Global Wound Care Biologics Market

The Global Wound Care Biologics market faces significant restraints due to the stringent regulatory approval processes associated with biologic wound care products. These rigorous protocols can prolong the time it takes for new products to enter the market, which not only hampers timely access for healthcare providers and patients but also escalates the overall development costs for manufacturers. As companies navigate through comprehensive testing and compliance requirements, the financial burden and extended timelines can deter innovation and the introduction of potentially beneficial solutions, ultimately impacting the growth and dynamics of the market.

Market Trends of the Global Wound Care Biologics Market

The Global Wound Care Biologics market is experiencing a significant trend towards personalized medicine, reflecting a broader healthcare shift in which treatments are customized to meet individual patient needs and specific wound characteristics. This tailored approach enhances treatment efficacy, as wound care biologics-such as growth factors, collagen-based products, and stem cell therapies-offer targeted healing solutions that address unique patient profiles. The rising prevalence of chronic wounds and advancements in biologic technologies further drive this market trend, pushing for innovations that integrate personalized strategies into standard wound care practices, thus improving patient outcomes and fostering competitive differentiation among market players.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Wound Care Biologics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Biological Skin Substitutes
  • Human Donor Tissue-derived Products
  • Acellular Animal-derived Products
  • Biosynthetic Products
• Topical Agents

Global Wound Care Biologics Market Size by Wound Type & CAGR (2025-2032)

• Market Overview
• Ulcers
  • Diabetic Foot Ulcers
  • Venous Ulcers
  • Pressure Ulcers
  • Other Ulcers
• Surgical & Traumatic Wounds
• Burns

Global Wound Care Biologics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Ambulatory Surgery Centers
• Burn Care Centers & Wound Clinics

Global Wound Care Biologics Market Size & CAGR (2025-2032)

• North America (Product, Wound Type, End User)
  • US
  • Canada
• Europe (Product, Wound Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Wound Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Wound Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Wound Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Smith & Nephew (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Integra LifeSciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organogenesis Holdings Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MiMedx Group, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Osiris Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aroa Biosurgery (New Zealand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avita Medical (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Derma Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alliqua BioMedical, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amnio Technology, LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tissue Regenix Group plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CollPlant Biotechnologies Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RenovaCare, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PolarityTE, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cytori Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Histogenics Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vericel Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RepliCel Life Sciences Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations